{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T17:09:06Z","timestamp":1778864946222,"version":"3.51.4"},"reference-count":329,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,6,25]],"date-time":"2014-06-25T00:00:00Z","timestamp":1403654400000},"content-version":"vor","delay-in-days":24,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/3.0\/"}],"funder":[{"DOI":"10.13039\/501100001102","name":"Cancer Council NSW","doi-asserted-by":"publisher","award":["PG 11-06"],"award-info":[{"award-number":["PG 11-06"]}],"id":[{"id":"10.13039\/501100001102","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1016699"],"award-info":[{"award-number":["1016699"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001171","name":"Cancer Institute NSW","doi-asserted-by":"publisher","award":["10\/TPG\/1-03"],"award-info":[{"award-number":["10\/TPG\/1-03"]}],"id":[{"id":"10.13039\/501100001171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001171","name":"Cancer Institute NSW","doi-asserted-by":"publisher","award":["11\/TRC\/1-03"],"award-info":[{"award-number":["11\/TRC\/1-03"]}],"id":[{"id":"10.13039\/501100001171","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["BBA Clinical"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.bbacli.2014.06.003","type":"journal-article","created":{"date-parts":[[2014,6,28]],"date-time":"2014-06-28T19:16:10Z","timestamp":1403982970000},"page":"59-77","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["Molecular profiling of childhood cancer: Biomarkers and novel therapies"],"prefix":"10.1016","volume":"1","author":[{"given":"Federica","family":"Saletta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol","family":"Wadham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David S.","family":"Ziegler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glenn M.","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Haber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geoffrey","family":"McCowage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murray D.","family":"Norris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer A.","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbacli.2014.06.003_bb0005","series-title":"Cancer Facts & Figs. 2014","author":"American Cancer Society","year":"2014"},{"issue":"4","key":"10.1016\/j.bbacli.2014.06.003_bb0010","first-page":"220","article-title":"Cancer treatment and survivorship statistics, 2012","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J. Clin."},{"issue":"2","key":"10.1016\/j.bbacli.2014.06.003_bb0015","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2165\/00148581-200709020-00002","article-title":"Emerging treatments and gene expression profiling in high-risk medulloblastoma","volume":"9","author":"Sardi","year":"2007","journal-title":"Paediatr. Drugs"},{"issue":"3","key":"10.1016\/j.bbacli.2014.06.003_bb0020","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3109\/10408363.2012.683483","article-title":"Neuroblastoma: the impact of biology and cooperation leading to personalized treatments","volume":"49","author":"Owens","year":"2012","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"issue":"10","key":"10.1016\/j.bbacli.2014.06.003_bb0025","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1158\/1078-0432.CCR-11-1936","article-title":"Advances in the genetics of high-risk childhood B-progenitor acute lymphoblastic leukemia and juvenile myelomonocytic leukemia: implications for therapy","volume":"18","author":"Loh","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"10 Suppl.","key":"10.1016\/j.bbacli.2014.06.003_bb0030","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1002\/cncr.26050","article-title":"Targeted therapy in pediatric and adolescent oncology","volume":"117","author":"Bernstein","year":"2011","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.bbacli.2014.06.003_bb0035","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9","article-title":"The Ki-67 protein: from the known and the unknown","volume":"182","author":"Scholzen","year":"2000","journal-title":"J. Cell. Physiol."},{"issue":"4","key":"10.1016\/j.bbacli.2014.06.003_bb0040","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.semcancer.2011.08.001","article-title":"The MYCN oncogene and differentiation in neuroblastoma","volume":"21","author":"Westermark","year":"2011","journal-title":"Semin. Cancer Biol."},{"issue":"3","key":"10.1016\/j.bbacli.2014.06.003_bb0045","first-page":"208","article-title":"Serum S100\u2014a marker for disease monitoring in metastatic melanoma","volume":"194","author":"Henze","year":"1997","journal-title":"Dermatology"},{"issue":"5","key":"10.1016\/j.bbacli.2014.06.003_bb0050","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/clpt.2009.297","article-title":"Targeted cancer therapies in the twenty-first century: lessons from imatinib","volume":"87","author":"Stegmeier","year":"2010","journal-title":"Clin. Pharmacol. Ther."},{"issue":"31","key":"10.1016\/j.bbacli.2014.06.003_bb0055","doi-asserted-by":"crossref","first-page":"5175","DOI":"10.1200\/JCO.2008.21.2514","article-title":"Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study","volume":"27","author":"Schultz","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.bbacli.2014.06.003_bb0060","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s11523-012-0227-8","article-title":"Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma","volume":"7","author":"La Madrid","year":"2012","journal-title":"Target. Oncol."},{"key":"10.1016\/j.bbacli.2014.06.003_bb0065","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2147\/DDDT.S19045","article-title":"Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond","volume":"5","author":"Ou","year":"2011","journal-title":"Drug Des. Dev. Ther."},{"issue":"Suppl. 3","key":"10.1016\/j.bbacli.2014.06.003_bb0070","first-page":"801","article-title":"Genetic predispositions and childhood cancer","volume":"106","author":"Shannon","year":"1998","journal-title":"Environ. Health Perspect."},{"key":"10.1016\/j.bbacli.2014.06.003_bb0075","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/1078155212473862","article-title":"Clinically relevant cancer biomarkers and pharmacogenetic assays","volume":"20","author":"Patel","year":"2014","journal-title":"J. Oncol. Pharm. Pract."},{"issue":"1","key":"10.1016\/j.bbacli.2014.06.003_bb0080","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1289\/ehp.9023","article-title":"Risk factors for acute leukemia in children: a review","volume":"115","author":"Belson","year":"2007","journal-title":"Environ. Health Perspect."},{"issue":"2","key":"10.1016\/j.bbacli.2014.06.003_bb0085","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.taap.2004.11.026","article-title":"Molecular biomarkers for the study of childhood leukemia","volume":"206","author":"Smith","year":"2005","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"4","key":"10.1016\/j.bbacli.2014.06.003_bb0090","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1365-2141.2012.09039.x","article-title":"Imatinib resistant BCR\u2013ABL1 mutations at relapse in children with Ph+ ALL: a Children's Oncology Group (COG) study","volume":"157","author":"Chang","year":"2012","journal-title":"Br. J. Haematol."},{"issue":"4","key":"10.1016\/j.bbacli.2014.06.003_bb0095","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2174\/138945011794751591","article-title":"Dasatinib: an anti-tumour agent via Src inhibition","volume":"12","author":"Gnoni","year":"2011","journal-title":"Curr. Drug Targets"},{"issue":"7","key":"10.1016\/j.bbacli.2014.06.003_bb0100","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1200\/JCO.2010.30.7231","article-title":"Pediatric phase I trial and pharmacokinetic study of dasatinib: a report from the children's oncology group phase I consortium","volume":"29","author":"Aplenc","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.bbacli.2014.06.003_bb0105","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2165\/00003495-200969020-00006","article-title":"Sorafenib: a review of its use in advanced hepatocellular carcinoma","volume":"69","author":"Keating","year":"2009","journal-title":"Drugs"},{"issue":"21","key":"10.1016\/j.bbacli.2014.06.003_bb0110","doi-asserted-by":"crossref","first-page":"6011","DOI":"10.1158\/1078-0432.CCR-11-3284","article-title":"A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report","volume":"18","author":"Widemann","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.bbacli.2014.06.003_bb0115","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.leukres.2010.04.004","article-title":"FLT3 and KIT mutated pediatric acute myeloid leukemia (AML) samples are sensitive in vitro to the tyrosine kinase inhibitor SU11657","volume":"34","author":"Goemans","year":"2010","journal-title":"Leuk. Res."},{"issue":"12","key":"10.1016\/j.bbacli.2014.06.003_bb0120","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1158\/1078-0432.CCR-12-0653","article-title":"U.S. Food and Drug Administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis","volume":"18","author":"Deisseroth","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"17","key":"10.1016\/j.bbacli.2014.06.003_bb0125","doi-asserted-by":"crossref","first-page":"3510","DOI":"10.1182\/blood-2012-03-415448","article-title":"Targeting JAK1\/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia","volume":"120","author":"Maude","year":"2012","journal-title":"Blood"},{"issue":"8, Supp 1","key":"10.1016\/j.bbacli.2014.06.003_bb0130","article-title":"AACR 103rd Annual Meeting, Abstract 867: Therapeutic potential of small molecule SYK inhibitors for treatment of primary B cell acute lymphoblastic leukemia","volume":"72","author":"Perova","year":"2012","journal-title":"Cancer Res."},{"issue":"21","key":"10.1016\/j.bbacli.2014.06.003_bb0135","doi-asserted-by":"crossref","first-page":"4348","DOI":"10.1182\/blood-2012-11-470633","article-title":"Nanoscale liposomal formulation of a SYK P-site inhibitor against B-precursor leukemia","volume":"121","author":"Uckun","year":"2013","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bbacli.2014.06.003_bb0140","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1055\/s-0031-1296196","article-title":"In vitro and in vivo chemosensitizing activity of LFM-A13, a dual-function inhibitor of Bruton's tyrosine kinase and polo-like kinases, against human leukemic B-cell precursors","volume":"61","author":"Uckun","year":"2011","journal-title":"Arzneimittelforschung"},{"issue":"6","key":"10.1016\/j.bbacli.2014.06.003_bb0145","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s11912-008-0073-0","article-title":"Pediatric developmental therapies: interesting new drugs now in early-stage clinical trials","volume":"10","author":"Macy","year":"2008","journal-title":"Curr. Oncol. Rep."},{"issue":"2","key":"10.1016\/j.bbacli.2014.06.003_bb0150","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/pbc.22775","article-title":"Phase 1 trial and pharmacokinetic study of the farnesyl transferase inhibitor tipifarnib in children and adolescents with refractory leukemias: a report from the Children's Oncology Group","volume":"56","author":"Widemann","year":"2011","journal-title":"Pediatr. Blood Cancer"},{"issue":"7","key":"10.1016\/j.bbacli.2014.06.003_bb0155","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.3324\/haematol.2011.046896","article-title":"Genetic disruption of the PI3K regulatory subunits, p85 alpha, p55 alpha, and p50 alpha, normalizes mutant PTPN11-induced hypersensitivity to GM-CSF","volume":"97","author":"Goodwin","year":"2012","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.bbacli.2014.06.003_bb0160","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/pbc.24301","article-title":"Initial testing (stage 1) of the phosphatidylinositol 3\u2032 kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program","volume":"60","author":"Reynolds","year":"2013","journal-title":"Pediatr. Blood Cancer"},{"issue":"9","key":"10.1016\/j.bbacli.2014.06.003_bb0165","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.leukres.2011.05.022","article-title":"Adaptation of the plasma inhibitory activity assay to detect Aurora, ABL and FLT3 kinase inhibition by AT9283 in pediatric leukemia","volume":"35","author":"Podesta","year":"2011","journal-title":"Leuk. Res."},{"issue":"7","key":"10.1016\/j.bbacli.2014.06.003_bb0170","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.3109\/10428194.2012.752079","article-title":"Occurrence and modulation of therapeutic targets of Aurora kinase inhibition in pediatric acute leukemia cells","volume":"54","author":"Jayanthan","year":"2013","journal-title":"Leuk. Lymphoma"},{"issue":"1","key":"10.1016\/j.bbacli.2014.06.003_bb0175","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/pbc.22430","article-title":"Initial testing of the aurora Kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP)","volume":"55","author":"Maris","year":"2010","journal-title":"Pediatr. Blood Cancer"},{"issue":"5","key":"10.1016\/j.bbacli.2014.06.003_bb0180","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1007\/s00280-011-1618-8","article-title":"Efficacy and pharmacokinetic\/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer","volume":"68","author":"Carol","year":"2011","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"3","key":"10.1016\/j.bbacli.2014.06.003_bb0185","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/pbc.21988","article-title":"Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program","volume":"53","author":"Keshelava","year":"2009","journal-title":"Pediatr. Blood Cancer"},{"issue":"22","key":"10.1016\/j.bbacli.2014.06.003_bb0190","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1200\/JCO.2009.25.9119","article-title":"Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report","volume":"28","author":"Fouladi","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.bbacli.2014.06.003_bb0195","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1203\/01.PDR.0000153871.45184.19","article-title":"Effects of 17-allylamino-17-demethoxygeldanamycin (17-AAG) on pediatric acute lymphoblastic leukemia (ALL) with respect to Bcr\u2013Abl status and imatinib mesylate sensitivity","volume":"57","author":"Hawkins","year":"2005","journal-title":"Pediatr. Res."},{"issue":"7","key":"10.1016\/j.bbacli.2014.06.003_bb0200","doi-asserted-by":"crossref","first-page":"E42","DOI":"10.1002\/pbc.24451","article-title":"Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the pediatric preclinical testing program","volume":"60","author":"Lock","year":"2013","journal-title":"Pediatr. Blood Cancer"},{"issue":"1","key":"10.1016\/j.bbacli.2014.06.003_bb0205","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1517\/14740338.6.1.53","article-title":"Safety of topotecan in the treatment of recurrent small-cell lung cancer and ovarian cancer","volume":"6","author":"Garst","year":"2007","journal-title":"Expert Opin. Drug Saf."},{"issue":"9","key":"10.1016\/j.bbacli.2014.06.003_bb0210","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1002\/cncr.23395","article-title":"Phase II study of topotecan in combination with dexamethasone, asparaginase, and vincristine in pediatric patients with acute lymphoblastic leukemia in first relapse","volume":"112","author":"Hijiya","year":"2008","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.bbacli.2014.06.003_bb0215","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/cncr.24712","article-title":"Combination of cladribine plus topotecan for recurrent or refractory pediatric acute myeloid leukemia","volume":"116","author":"Inaba","year":"2010","journal-title":"Cancer"},{"issue":"6 Suppl. 9","key":"10.1016\/j.bbacli.2014.06.003_bb0220","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1053\/j.seminoncol.2005.04.022","article-title":"Front-line therapy for advanced colorectal cancer: emphasis on chemotherapy","volume":"32","author":"Varadhachary","year":"2005","journal-title":"Semin. Oncol."},{"issue":"10","key":"10.1016\/j.bbacli.2014.06.003_bb0225","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.leukres.2008.12.003","article-title":"Chemo-sensitivity in a panel of B-cell precursor acute lymphoblastic leukemia cell lines, YCUB series, derived from children","volume":"33","author":"Goto","year":"2009","journal-title":"Leuk. Res."},{"issue":"12","key":"10.1016\/j.bbacli.2014.06.003_bb0230","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/leu.2009.185","article-title":"A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia","volume":"23","author":"Hijiya","year":"2009","journal-title":"Leukemia"},{"issue":"23","key":"10.1016\/j.bbacli.2014.06.003_bb0235","doi-asserted-by":"crossref","first-page":"6043","DOI":"10.1182\/blood-2011-08-374710","article-title":"Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia","volume":"118","author":"Hijiya","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bbacli.2014.06.003_bb0240","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/pbc.21214","article-title":"Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program","volume":"50","author":"Houghton","year":"2008","journal-title":"Pediatr. Blood Cancer"},{"issue":"5","key":"10.1016\/j.bbacli.2014.06.003_bb0245","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1158\/1078-0432.CCR-06-2173","article-title":"A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study","volume":"13","author":"Horton","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bbacli.2014.06.003_bb0250","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00280-005-0135-z","article-title":"Bortezomib interactions with chemotherapy agents in acute leukemia in vitro","volume":"58","author":"Horton","year":"2006","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"2","key":"10.1016\/j.bbacli.2014.06.003_bb0255","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/pbc.22456","article-title":"Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium","volume":"55","author":"Messinger","year":"2010","journal-title":"Pediatr. Blood Cancer"},{"issue":"2","key":"10.1016\/j.bbacli.2014.06.003_bb0260","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood-2012-04-418640","article-title":"Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study","volume":"120","author":"Messinger","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbacli.2014.06.003_bb0265","doi-asserted-by":"crossref","unstructured":"Vedi, A., and D.S. Ziegler, Antibody therapy for pediatric leukemia. Front Oncol, 4: 82.","DOI":"10.3389\/fonc.2014.00082"},{"issue":"19","key":"10.1016\/j.bbacli.2014.06.003_bb0270","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1200\/JCO.2009.26.6791","article-title":"Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia","volume":"28","author":"Meinhardt","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.bbacli.2014.06.003_bb0275","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/pbc.21753","article-title":"A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent\/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group","volume":"52","author":"Griffin","year":"2009","journal-title":"Pediatr. Blood Cancer"},{"issue":"6","key":"10.1016\/j.bbacli.2014.06.003_bb0280","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1002\/pbc.22209","article-title":"A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: a Children's Oncology Group report","volume":"53","author":"Angiolillo","year":"2009","journal-title":"Pediatr. Blood Cancer"},{"issue":"11","key":"10.1016\/j.bbacli.2014.06.003_bb0285","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1016\/j.bbmt.2012.05.006","article-title":"Busulfan, fludarabine, and alemtuzumab as a reduced toxicity regimen for children with malignant and nonmalignant diseases improves engraftment and graft-versus-host disease without delaying immune reconstitution","volume":"18","author":"Law","year":"2012","journal-title":"Biol. Blood. Marrow. Transplant."},{"issue":"4","key":"10.1016\/j.bbacli.2014.06.003_bb0290","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/nrc3236","article-title":"Antibody therapy of cancer","volume":"12","author":"Scott","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"20","key":"10.1016\/j.bbacli.2014.06.003_bb0295","doi-asserted-by":"crossref","first-page":"6300","DOI":"10.1158\/0008-5472.CAN-11-1374","article-title":"Treatment of hematologic malignancies with immunotoxins and antibody\u2013drug conjugates","volume":"71","author":"FitzGerald","year":"2011","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.bbacli.2014.06.003_bb0300","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2217\/imt.10.114","article-title":"Cancer radioimmunotherapy","volume":"3","author":"Sharkey","year":"2011","journal-title":"Immunotherapy"},{"issue":"4","key":"10.1016\/j.bbacli.2014.06.003_bb0305","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood-2004-10-3821","article-title":"Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia","volume":"106","author":"Arceci","year":"2005","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.bbacli.2014.06.003_bb0310","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1200\/JCO.2007.13.0096","article-title":"Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukemia: a report from the Children's Oncology Group","volume":"26","author":"Aplenc","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbacli.2014.06.003_bb0315","first-page":"118","article-title":"A novel anti-CD22 immunotoxin, moxetumomab pasudotox: phase I study in pediatric acute lymphoblastic leukemia (ALL)","author":"Wayne","year":"2011","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bbacli.2014.06.003_bb0320","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/pbc.24721","article-title":"Initial experience with CMC-544 (inotuzumab ozogamicin) in pediatric patients with relapsed B-cell acute lymphocytic leukaemia","volume":"61","author":"Rytting","year":"2014","journal-title":"Pediatr. Blood Cancer"},{"issue":"7","key":"10.1016\/j.bbacli.2014.06.003_bb0325","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1158\/1078-0432.CCR-12-3613","article-title":"The anti-CD19 antibody\u2013drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia","volume":"19","author":"Carol","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbacli.2014.06.003_bb0330","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3389\/fonc.2014.00063","article-title":"Blinatumomab, a bi-specific anti-CD19\/CD3 BiTE\u00ae antibody for the treatment of acute lymphoblastic leukemia: perspectives and current pediatric applications","volume":"4","author":"Hoffman","year":"2014","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.bbacli.2014.06.003_bb0335","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/leu.2010.239","article-title":"Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia","volume":"25","author":"Handgretinger","year":"2011","journal-title":"Leukemia"},{"issue":"21","key":"10.1016\/j.bbacli.2014.06.003_bb0340","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1182\/blood.V122.21.70.70","article-title":"A phase 1\/2 study of blinatumomab in pediatric patients with relapsed\/refractory B-cell precursor acute lymphoblastic leukemia","volume":"122","author":"von Stackelberg","year":"2013","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.bbacli.2014.06.003_bb0345","doi-asserted-by":"crossref","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","article-title":"Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity","volume":"86","author":"Gross","year":"1989","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"10","key":"10.1016\/j.bbacli.2014.06.003_bb0350","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1158\/1078-0432.CCR-11-1920","article-title":"The future is now: chimeric antigen receptors as new targeted therapies for childhood cancer","volume":"18","author":"Lee","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.bbacli.2014.06.003_bb0355","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1182\/blood-2007-12-128843","article-title":"Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells","volume":"112","author":"Till","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbacli.2014.06.003_bb0360","first-page":"120","article-title":"ASH Annual Meeting, Abstracts 120: CD19 targeted allogeneic EBV-specific T cells for the treatment of relapsed ALL in pediatric patients post HSCT","author":"Curran","year":"2012","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.bbacli.2014.06.003_bb0365","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbacli.2014.06.003_bb0370","doi-asserted-by":"crossref","unstructured":"Napper, A.D. and Watson V.G., Targeted drug discovery for pediatric leukemia. Front Oncol, 3: 170","DOI":"10.3389\/fonc.2013.00170"},{"issue":"6","key":"10.1016\/j.bbacli.2014.06.003_bb0375","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1002\/pbc.24433","article-title":"Children's Oncology Group's 2013 blueprint for research: neuroblastoma","volume":"60","author":"Park","year":"2013","journal-title":"Pediatr. Blood Cancer"},{"issue":"25","key":"10.1016\/j.bbacli.2014.06.003_bb0380","doi-asserted-by":"crossref","first-page":"10258","DOI":"10.1073\/pnas.1222404110","article-title":"MYC inhibition induces metabolic changes leading to accumulation of lipid droplets in tumor cells","volume":"110","author":"Zirath","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"40","key":"10.1016\/j.bbacli.2014.06.003_bb0385","doi-asserted-by":"crossref","first-page":"16669","DOI":"10.1073\/pnas.1108190108","article-title":"Targeting MYC dependence in cancer by inhibiting BET bromodomains","volume":"108","author":"Mertz","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"37","key":"10.1016\/j.bbacli.2014.06.003_bb0390","doi-asserted-by":"crossref","first-page":"5521","DOI":"10.1038\/sj.onc.1210618","article-title":"Structure and acetyl-lysine recognition of the bromodomain","volume":"26","author":"Mujtaba","year":"2007","journal-title":"Oncogene"},{"issue":"7370","key":"10.1016\/j.bbacli.2014.06.003_bb0395","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nature10334","article-title":"RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia","volume":"478","author":"Zuber","year":"2011","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.bbacli.2014.06.003_bb0400","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1158\/2159-8290.CD-12-0418","article-title":"Targeting MYCN in neuroblastoma by BET bromodomain inhibition","volume":"3","author":"Puissant","year":"2013","journal-title":"Cancer Discov."},{"issue":"7152","key":"10.1016\/j.bbacli.2014.06.003_bb0405","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nature05953","article-title":"Non-transcriptional control of DNA replication by c-Myc","volume":"448","author":"Dominguez-Sola","year":"2007","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.bbacli.2014.06.003_bb0410","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1073\/pnas.1012351108","article-title":"RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma","volume":"108","author":"Cole","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"20","key":"10.1016\/j.bbacli.2014.06.003_bb0415","doi-asserted-by":"crossref","first-page":"5650","DOI":"10.1158\/1078-0432.CCR-12-1322","article-title":"CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs","volume":"18","author":"Walton","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"1\u20132","key":"10.1016\/j.bbacli.2014.06.003_bb0420","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0304-3835(03)00108-3","article-title":"Retinoid therapy of high-risk neuroblastoma","volume":"197","author":"Reynolds","year":"2003","journal-title":"Cancer Lett."},{"issue":"13","key":"10.1016\/j.bbacli.2014.06.003_bb0425","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1093\/jnci\/91.13.1138","article-title":"Increase of ceramide and induction of mixed apoptosis\/necrosis by N-(4-hydroxyphenyl)- retinamide in neuroblastoma cell lines","volume":"91","author":"Maurer","year":"1999","journal-title":"J. Natl. Cancer Inst."},{"issue":"6","key":"10.1016\/j.bbacli.2014.06.003_bb0430","first-page":"2032","article-title":"Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma","volume":"9","author":"Garaventa","year":"2003","journal-title":"Clin. Cancer Res."},{"issue":"21","key":"10.1016\/j.bbacli.2014.06.003_bb0435","doi-asserted-by":"crossref","first-page":"6858","DOI":"10.1158\/1078-0432.CCR-11-0995","article-title":"Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR\/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children's Oncology Group","volume":"17","author":"Villablanca","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.bbacli.2014.06.003_bb0440","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.jconrel.2013.06.015","article-title":"Enhanced anti-tumor and anti-angiogenic efficacy of a novel liposomal fenretinide on human neuroblastoma","volume":"170","author":"Di Paolo","year":"2013","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.bbacli.2014.06.003_bb0445","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1345\/aph.1R353","article-title":"Targeted immunotherapy for high-risk neuroblastoma\u2014the role of monoclonal antibodies","volume":"47","author":"Parsons","year":"2013","journal-title":"Ann. Pharmacother."},{"issue":"14","key":"10.1016\/j.bbacli.2014.06.003_bb0450","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1056\/NEJMoa0911123","article-title":"Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma","volume":"363","author":"Yu","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.bbacli.2014.06.003_bb0455","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1200\/JCO.2013.50.4423","article-title":"Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma","volume":"32","author":"Navid","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.bbacli.2014.06.003_bb0460","doi-asserted-by":"crossref","first-page":"729","DOI":"10.2174\/156800909789271521","article-title":"The PI3K\/Akt\/mTOR pathway as therapeutic target in neuroblastoma","volume":"9","author":"Fulda","year":"2009","journal-title":"Curr. Cancer Drug Targets"},{"issue":"4","key":"10.1016\/j.bbacli.2014.06.003_bb0465","first-page":"192","article-title":"Analysis of PI3K\/AKT\/mTOR signalling pathway in high risk neuroblastic tumours","volume":"61","author":"Izycka-Swieszewska","year":"2010","journal-title":"Pol. J. Pathol."},{"issue":"11","key":"10.1016\/j.bbacli.2014.06.003_bb0470","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/jnci\/djq125","article-title":"In vitro and in vivo inhibition of neuroblastoma tumor cell growth by AKT inhibitor perifosine","volume":"102","author":"Li","year":"2010","journal-title":"J. Natl. Cancer Inst."},{"issue":"23","key":"10.1016\/j.bbacli.2014.06.003_bb0475","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1002\/cncr.26133","article-title":"Perifosine-induced inhibition of Akt attenuates brain-derived neurotrophic factor\/TrkB-induced chemoresistance in neuroblastoma in vivo","volume":"117","author":"Li","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.bbacli.2014.06.003_bb0480","series-title":"ANR 2012, Abstract POC27: Targeting the PI3K\/Akt Pathway: Perifosine Monotherapy for Resistant Neuroblastoma (NB) in a Phase I\/Ib Study","author":"Kushner","year":"2012"},{"key":"10.1016\/j.bbacli.2014.06.003_bb0485","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3389\/fnmol.2011.00051","article-title":"PI3K\/AKT\/mTOR pathway in angiogenesis","volume":"4","author":"Karar","year":"2011","journal-title":"Front. Mol. Neurosci."},{"issue":"21","key":"10.1016\/j.bbacli.2014.06.003_bb0490","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1200\/JCO.2010.33.4649","article-title":"Phase I study of temsirolimus in pediatric patients with recurrent\/refractory solid tumors","volume":"29","author":"Spunt","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.bbacli.2014.06.003_bb0495","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ejca.2011.09.021","article-title":"Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma","volume":"48","author":"Geoerger","year":"2012","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"10.1016\/j.bbacli.2014.06.003_bb0500","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00280-010-1486-7","article-title":"The PI-3 kinase\u2013Akt\u2013MDM2\u2013survivin signaling axis in high-risk neuroblastoma: a target for PI-3 kinase inhibitor intervention","volume":"68","author":"Peirce","year":"2011","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"10","key":"10.1016\/j.bbacli.2014.06.003_bb0505","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1158\/1078-0432.CCR-10-2530","article-title":"Targeting aberrant PI3K\/Akt activation by PI103 restores sensitivity to TRAIL-induced apoptosis in neuroblastoma","volume":"17","author":"Opel","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.bbacli.2014.06.003_bb0510","doi-asserted-by":"crossref","first-page":"2958","DOI":"10.1002\/ijc.26268","article-title":"Effects of small molecule inhibitors of PI3K\/Akt\/mTOR signaling on neuroblastoma growth in vitro and in vivo","volume":"129","author":"Segerstr\u00f6m","year":"2011","journal-title":"Int. J. Cancer"},{"issue":"115","key":"10.1016\/j.bbacli.2014.06.003_bb0515","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002977","article-title":"Paracrine signaling through MYCN enhances tumor\u2013vascular interactions in neuroblastoma","volume":"4","author":"Chanthery","year":"2012","journal-title":"Sci. Transl. Med."},{"issue":"11","key":"10.1016\/j.bbacli.2014.06.003_bb0520","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1002\/ijc.27935","article-title":"The dual PI3K\/mTOR inhibitor NVP-BEZ235 and chloroquine synergize to trigger apoptosis via mitochondrial-lysosomal cross-talk","volume":"132","author":"Seitz","year":"2013","journal-title":"Int. J. Cancer"},{"issue":"7215","key":"10.1016\/j.bbacli.2014.06.003_bb0525","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1038\/nature07261","article-title":"Identification of ALK as a major familial neuroblastoma predisposition gene","volume":"455","author":"Mosse","year":"2008","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.bbacli.2014.06.003_bb0530","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.semcancer.2011.09.005","article-title":"Emerging importance of ALK in neuroblastoma","volume":"21","author":"Azarova","year":"2011","journal-title":"Semin. Cancer Biol."},{"issue":"18","key":"10.1016\/j.bbacli.2014.06.003_bb0535","doi-asserted-by":"crossref","first-page":"7338","DOI":"10.1158\/0008-5472.CAN-08-4419","article-title":"Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients","volume":"69","author":"Passoni","year":"2009","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.bbacli.2014.06.003_bb0540","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S1470-2045(13)70095-0","article-title":"Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study","volume":"14","author":"Mosse","year":"2013","journal-title":"Lancet Oncol."},{"issue":"15 Suppl.","key":"10.1016\/j.bbacli.2014.06.003_bb0545","article-title":"ASCO Annual Meeting, Abstract 3007: First-in-human phase I study of the ALK inhibitor LDK378 in advanced solid tumours","volume":"30","author":"Mehra","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"30","key":"10.1016\/j.bbacli.2014.06.003_bb0550","doi-asserted-by":"crossref","first-page":"4921","DOI":"10.1200\/JCO.2007.15.2306","article-title":"Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study","volume":"26","author":"Jakacki","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bbacli.2014.06.003_bb0555","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/pbc.22219","article-title":"Gefitinib in combination with oral topotecan and cyclophosphamide in relapsed neuroblastoma: pharmacological rationale and clinical response","volume":"54","author":"Donfrancesco","year":"2010","journal-title":"Pediatr. Blood Cancer"},{"issue":"4","key":"10.1016\/j.bbacli.2014.06.003_bb0560","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1007\/s10637-011-9724-3","article-title":"A single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma","volume":"30","author":"Furman","year":"2012","journal-title":"Invest. New Drugs"},{"issue":"13","key":"10.1016\/j.bbacli.2014.06.003_bb0565","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1002\/cncr.25073","article-title":"Signaling of ERBB receptor tyrosine kinases promotes neuroblastoma growth in vitro and in vivo","volume":"116","author":"Richards","year":"2010","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.bbacli.2014.06.003_bb0570","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s00280-011-1581-4","article-title":"Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study","volume":"68","author":"Minturn","year":"2011","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"5","key":"10.1016\/j.bbacli.2014.06.003_bb0575","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1158\/1078-0432.CCR-09-1531","article-title":"Lestaurtinib enhances the antitumor efficacy of chemotherapy in murine xenograft models of neuroblastoma","volume":"16","author":"Iyer","year":"2010","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.bbacli.2014.06.003_bb0580","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00280-012-1879-x","article-title":"AZ64 inhibits TrkB and enhances the efficacy of chemotherapy and local radiation in neuroblastoma xenografts","volume":"70","author":"Iyer","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"6","key":"10.1016\/j.bbacli.2014.06.003_bb0585","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1002\/cncr.25674","article-title":"The selective Trk inhibitor AZ623 inhibits brain-derived neurotrophic factor-mediated neuroblastoma cell proliferation and signaling and is synergistic with topotecan","volume":"117","author":"Zage","year":"2011","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.bbacli.2014.06.003_bb0590","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1002\/cncr.25017","article-title":"A novel therapeutic combination for neuroblastoma: the vascular endothelial growth factor receptor\/epidermal growth factor receptor\/rearranged during transfection inhibitor vandetanib with 13-cis-retinoic acid","volume":"116","author":"Zage","year":"2010","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.bbacli.2014.06.003_bb0595","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1158\/1535-7163.MCT-07-0568","article-title":"Potent antitumor effects of ZD6474 on neuroblastoma via dual targeting of tumor cells and tumor endothelium","volume":"7","author":"Beaudry","year":"2008","journal-title":"Mol. Cancer Ther."},{"issue":"3","key":"10.1016\/j.bbacli.2014.06.003_bb0600","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/pbc.21232","article-title":"Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program","volume":"50","author":"Maris","year":"2008","journal-title":"Pediatr. Blood Cancer"},{"issue":"4","key":"10.1016\/j.bbacli.2014.06.003_bb0605","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/pbc.23159","article-title":"Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program","volume":"58","author":"Morton","year":"2012","journal-title":"Pediatr. Blood Cancer"},{"issue":"4","key":"10.1016\/j.bbacli.2014.06.003_bb0610","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1158\/0008-5472.CAN-10-2484","article-title":"Small molecule kinase inhibitor screen identifies polo-like kinase 1 as a target for neuroblastoma tumor-initiating cells","volume":"71","author":"Grinshtein","year":"2011","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.bbacli.2014.06.003_bb0615","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1097\/CAD.0b013e3283454526","article-title":"An in-vitro evaluation of the polo-like kinase inhibitor GW843682X against paediatric malignancies","volume":"22","author":"Spaniol","year":"2011","journal-title":"Anticancer Drugs"},{"issue":"2","key":"10.1016\/j.bbacli.2014.06.003_bb0620","first-page":"353","article-title":"In vitro antiproliferative and antimigratory activity of dasatinib in neuroblastoma and Ewing sarcoma cell lines","volume":"19","author":"Timeus","year":"2008","journal-title":"Oncol. Rep."},{"issue":"11","key":"10.1016\/j.bbacli.2014.06.003_bb0625","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1002\/ijc.24606","article-title":"Activity of tyrosine kinase inhibitor dasatinib in neuroblastoma cells in vitro and in orthotopic mouse model","volume":"125","author":"Vitali","year":"2009","journal-title":"Int. J. Cancer"},{"issue":"4","key":"10.1016\/j.bbacli.2014.06.003_bb0630","first-page":"443","article-title":"Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma","volume":"71","author":"Keisner","year":"2011","journal-title":"Drugs"},{"issue":"17","key":"10.1016\/j.bbacli.2014.06.003_bb0635","doi-asserted-by":"crossref","first-page":"5656","DOI":"10.1158\/1078-0432.CCR-11-0078","article-title":"Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor","volume":"17","author":"Kumar","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.bbacli.2014.06.003_bb0640","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/pbc.24004","article-title":"Sorafenib inhibits neuroblastoma cell proliferation and signaling, blocks angiogenesis, and impairs tumor growth","volume":"59","author":"Kakodkar","year":"2012","journal-title":"Pediatr. Blood Cancer"},{"issue":"1","key":"10.1016\/j.bbacli.2014.06.003_bb0645","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1634\/theoncologist.12-1-107","article-title":"Food and Drug Administration drug approval summary: sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma","volume":"12","author":"Rock","year":"2007","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.bbacli.2014.06.003_bb0650","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1593\/neo.09166","article-title":"In vivo antitumor and antimetastatic activity of sunitinib in preclinical neuroblastoma mouse model","volume":"11","author":"Zhang","year":"2009","journal-title":"Neoplasia"},{"issue":"1","key":"10.1016\/j.bbacli.2014.06.003_bb0655","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1021\/jm1011319","article-title":"Discovery of 5-chloro-N2-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)p yrimidine-2,4-diamine (AZD1480) as a novel inhibitor of the Jak\/Stat pathway","volume":"54","author":"Ioannidis","year":"2011","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bbacli.2014.06.003_bb0660","doi-asserted-by":"crossref","first-page":"433","DOI":"10.18632\/oncotarget.930","article-title":"Inhibition of STAT3 with orally active JAK inhibitor, AZD1480, decreases tumor growth in neuroblastoma and pediatric sarcomas in vitro and in vivo","volume":"4","author":"Yan","year":"2013","journal-title":"Oncotarget"},{"issue":"21","key":"10.1016\/j.bbacli.2014.06.003_bb0665","doi-asserted-by":"crossref","first-page":"6058","DOI":"10.1158\/1078-0432.CCR-11-3251","article-title":"Pediatric phase I trial and pharmacokinetic study of MLN8237, an investigational oral selective small-molecule inhibitor of Aurora kinase A: a Children's Oncology Group Phase I Consortium study","volume":"18","author":"Mosse","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bbacli.2014.06.003_bb0670","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s10637-012-9831-9","article-title":"Additive effects of vorinostat and MLN8237 in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines","volume":"31","author":"Muscal","year":"2013","journal-title":"Invest. New Drugs"},{"issue":"3","key":"10.1016\/j.bbacli.2014.06.003_bb0675","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/pbc.24271","article-title":"A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children's Oncology Group phase I consortium study (ADVL0916)","volume":"60","author":"Muscal","year":"2013","journal-title":"Pediatr. Blood Cancer"},{"issue":"9","key":"10.1016\/j.bbacli.2014.06.003_bb0680","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.4161\/cc.9.9.11543","article-title":"Romidepsin (FK228\/depsipeptide) controls growth and induces apoptosis in neuroblastoma tumor cells","volume":"9","author":"Panicker","year":"2010","journal-title":"Cell Cycle"},{"issue":"21","key":"10.1016\/j.bbacli.2014.06.003_bb0685","first-page":"6108","article-title":"MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors","volume":"62","author":"Jaboin","year":"2002","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.bbacli.2014.06.003_bb0690","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1200\/JCO.2008.18.5918","article-title":"Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study","volume":"27","author":"Wagner","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.bbacli.2014.06.003_bb0695","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1200\/JCO.2010.31.7107","article-title":"Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study","volume":"29","author":"Bagatell","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"33","key":"10.1016\/j.bbacli.2014.06.003_bb0700","doi-asserted-by":"crossref","first-page":"5271","DOI":"10.1200\/JCO.2006.06.7272","article-title":"Irinotecan plus temozolomide for relapsed or refractory neuroblastoma","volume":"24","author":"Kushner","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbacli.2014.06.003_bb0705","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/1471-2407-12-101","article-title":"Synthetic lethal screen identifies NF-kappaB as a target for combination therapy with topotecan for patients with neuroblastoma","volume":"12","author":"Tsang","year":"2012","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.bbacli.2014.06.003_bb0710","doi-asserted-by":"crossref","first-page":"535","DOI":"10.18632\/oncotarget.498","article-title":"A chemical screen identifies the chemotherapeutic drug topotecan as a specific inhibitor of the B-MYB\/MYCN axis in neuroblastoma","volume":"3","author":"Sottile","year":"2012","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.bbacli.2014.06.003_bb0715","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/MPH.0b013e3180320b48","article-title":"Topotecan and etoposide in the treatment of relapsed high-risk neuroblastoma: results of a phase 2 trial","volume":"29","author":"Simon","year":"2007","journal-title":"J. Pediatr. Hematol. Oncol."},{"issue":"9","key":"10.1016\/j.bbacli.2014.06.003_bb0720","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s00432-007-0216-y","article-title":"Topotecan, cyclophosphamide, and etoposide (TCE) in the treatment of high-risk neuroblastoma. Results of a phase-II trial","volume":"133","author":"Simon","year":"2007","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"24","key":"10.1016\/j.bbacli.2014.06.003_bb0725","doi-asserted-by":"crossref","first-page":"3808","DOI":"10.1200\/JCO.2009.27.5016","article-title":"Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children's Oncology Group study","volume":"28","author":"London","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.bbacli.2014.06.003_bb0730","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/cncr.27783","article-title":"Ifosfamide, carboplatin, and etoposide for neuroblastoma: a high-dose salvage regimen and review of the literature","volume":"119","author":"Kushner","year":"2013","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.bbacli.2014.06.003_bb0735","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s00280-012-1973-0","article-title":"Preclinical evaluation of the novel 7-substituted camptothecin Namitecan (ST1968) in paediatric tumour models","volume":"70","author":"Meco","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"4","key":"10.1016\/j.bbacli.2014.06.003_bb0740","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s00280-009-1201-8","article-title":"Antitumor activity and pharmacokinetics of oral gimatecan on pediatric cancer xenografts","volume":"66","author":"Zucchetti","year":"2010","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"8","key":"10.1016\/j.bbacli.2014.06.003_bb0745","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.bcp.2005.07.009","article-title":"The novel lipophilic camptothecin analogue gimatecan is very active in vitro in human neuroblastoma: a comparative study with SN38 and topotecan","volume":"70","author":"Di Francesco","year":"2005","journal-title":"Biochem. Pharmacol."},{"issue":"19","key":"10.1016\/j.bbacli.2014.06.003_bb0750","doi-asserted-by":"crossref","first-page":"4809","DOI":"10.1158\/1078-0432.CCR-10-1354","article-title":"Tumor regression and curability of preclinical neuroblastoma models by PEGylated SN38 (EZN-2208), a novel topoisomerase I inhibitor","volume":"16","author":"Pastorino","year":"2010","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bbacli.2014.06.003_bb0755","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/pbc.22639","article-title":"The quinoxaline anti-tumor agent (R+)XK469 inhibits neuroblastoma tumor growth","volume":"56","author":"Kakodkar","year":"2011","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.bbacli.2014.06.003_bb0760","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3389\/fonc.2012.00162","article-title":"Polyamine pathway inhibition as a novel therapeutic approach to treating neuroblastoma","volume":"2","author":"Gamble","year":"2012","journal-title":"Front. Oncol."},{"issue":"23","key":"10.1016\/j.bbacli.2014.06.003_bb0765","doi-asserted-by":"crossref","first-page":"9735","DOI":"10.1158\/0008-5472.CAN-07-6866","article-title":"ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma","volume":"68","author":"Hogarty","year":"2008","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.bbacli.2014.06.003_bb0770","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/ijc.20611","article-title":"Hsp90 inhibitors deplete key anti-apoptotic proteins in pediatric solid tumor cells and demonstrate synergistic anticancer activity with cisplatin","volume":"113","author":"Bagatell","year":"2005","journal-title":"Int. J. Cancer"},{"issue":"6","key":"10.1016\/j.bbacli.2014.06.003_bb0775","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/pbc.23270","article-title":"Anti-tumor activity of the HSP90 inhibitor SNX-2112 in pediatric cancer cell lines","volume":"58","author":"Chinn","year":"2012","journal-title":"Pediatr. Blood Cancer"},{"issue":"2","key":"10.1016\/j.bbacli.2014.06.003_bb0780","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1517\/14728214.2013.796927","article-title":"Emerging drugs for neuroblastoma","volume":"18","author":"Castel","year":"2013","journal-title":"Expert Opin. Emerg. Drugs"},{"issue":"4","key":"10.1016\/j.bbacli.2014.06.003_bb0785","first-page":"80","article-title":"Brain tumors in children","volume":"42","author":"Fleming","year":"2012","journal-title":"Curr. Probl. Pediatr. Adolesc. Health Care"},{"issue":"3","key":"10.1016\/j.bbacli.2014.06.003_bb0790","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1743-7563.2012.01558.x","article-title":"Pediatric neuro-oncology: current status and future directions","volume":"8","author":"Heath","year":"2012","journal-title":"Asia Pac. J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.bbacli.2014.06.003_bb0795","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1586\/14737140.6.8.1187","article-title":"Temozolomide: a milestone in neuro-oncology and beyond?","volume":"6","author":"Mutter","year":"2006","journal-title":"Expert. Rev. Anticancer. Ther."},{"issue":"10","key":"10.1016\/j.bbacli.2014.06.003_bb0800","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.bbacli.2014.06.003_bb0805","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1200\/JCO.2002.20.5.1375","article-title":"Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide","volume":"20","author":"Stupp","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.bbacli.2014.06.003_bb0810","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1215\/15228517-2006-030","article-title":"Temozolomide in children with progressive low-grade glioma","volume":"9","author":"Gururangan","year":"2007","journal-title":"Neuro Oncol."},{"issue":"4","key":"10.1016\/j.bbacli.2014.06.003_bb0815","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1093\/neuonc\/noq205","article-title":"Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children's Oncology Group","volume":"13","author":"Cohen","year":"2011","journal-title":"Neuro Oncol."},{"issue":"22 Pt 1","key":"10.1016\/j.bbacli.2014.06.003_bb0820","doi-asserted-by":"crossref","first-page":"6712","DOI":"10.1158\/1078-0432.CCR-07-1016","article-title":"Phase I trial of single-dose temozolomide and continuous administration of o6-benzylguanine in children with brain tumors: a pediatric brain tumor consortium report","volume":"13","author":"Broniscer","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.bbacli.2014.06.003_bb0825","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s11060-011-0709-z","article-title":"A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium study","volume":"106","author":"Warren","year":"2012","journal-title":"J. Neurooncol."},{"issue":"133","key":"10.1016\/j.bbacli.2014.06.003_bb0830","doi-asserted-by":"crossref","first-page":"133ra57","DOI":"10.1126\/scitranslmed.3003425","article-title":"Extended survival of glioblastoma patients after chemoprotective HSC gene therapy","volume":"4","author":"Adair","year":"2012","journal-title":"Sci. Transl. Med."},{"issue":"10","key":"10.1016\/j.bbacli.2014.06.003_bb0835","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1038\/sj.bjc.6605946","article-title":"Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699","volume":"103","author":"Daniel","year":"2010","journal-title":"Br. J. Cancer"},{"issue":"12","key":"10.1016\/j.bbacli.2014.06.003_bb0840","doi-asserted-by":"crossref","first-page":"984","DOI":"10.18632\/oncotarget.362","article-title":"PARP inhibition sensitizes childhood high grade glioma, medulloblastoma and ependymoma to radiation","volume":"2","author":"van Vuurden","year":"2011","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.bbacli.2014.06.003_bb0845","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1586\/ern.12.66","article-title":"Molecular subgroups of medulloblastoma","volume":"12","author":"Northcott","year":"2012","journal-title":"Expert. Rev. Neurother."},{"issue":"51","key":"10.1016\/j.bbacli.2014.06.003_bb0850","doi-asserted-by":"crossref","first-page":"51ra70","DOI":"10.1126\/scitranslmed.3001599","article-title":"Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma","volume":"2","author":"Buonamici","year":"2010","journal-title":"Sci. Transl. Med."},{"issue":"3","key":"10.1016\/j.bbacli.2014.06.003_bb0855","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ccr.2004.08.019","article-title":"Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1(+\/\u2212)p53(\u2212\/\u2212) mice","volume":"6","author":"Romer","year":"2004","journal-title":"Cancer Cell"},{"issue":"8","key":"10.1016\/j.bbacli.2014.06.003_bb0860","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1158\/0008-5472.CAN-07-0493","article-title":"Medulloblastomas derived from Cxcr6 mutant mice respond to treatment with a smoothened inhibitor","volume":"67","author":"Sasai","year":"2007","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.bbacli.2014.06.003_bb0865","first-page":"707","article-title":"Vismodegib, a small-molecule inhibitor of the hedgehog pathway for the treatment of advanced cancers","volume":"11","author":"De Smaele","year":"2010","journal-title":"Curr. Opin. Investig. Drugs"},{"issue":"14","key":"10.1016\/j.bbacli.2014.06.003_bb0870","doi-asserted-by":"crossref","first-page":"4682","DOI":"10.1158\/1078-0432.CCR-11-0975","article-title":"Pharmacokinetic\u2013pharmacodynamic analysis of vismodegib in preclinical models of mutational and ligand-dependent Hedgehog pathway activation","volume":"17","author":"Wong","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.bbacli.2014.06.003_bb0875","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1056\/NEJMoa0902903","article-title":"Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449","volume":"361","author":"Rudin","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.bbacli.2014.06.003_bb0880","doi-asserted-by":"crossref","first-page":"E33","DOI":"10.1002\/ijc.27349","article-title":"In vitro and in vivo characterization of a novel Hedgehog signaling antagonist in human glioblastoma cell lines","volume":"131","author":"Ferruzzi","year":"2012","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.bbacli.2014.06.003_bb0885","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1158\/1535-7163.MCT-11-0691","article-title":"Effective targeting of Hedgehog signaling in a medulloblastoma model with PF-5274857, a potent and selective Smoothened antagonist that penetrates the blood\u2013brain barrier","volume":"11","author":"Rohner","year":"2012","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.bbacli.2014.06.003_bb0890","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/pbc.24142","article-title":"A feasibility and efficacy study of rapamycin and erlotinib for recurrent pediatric low-grade glioma (LGG)","volume":"60","author":"Yalon","year":"2013","journal-title":"Pediatr. Blood Cancer"},{"issue":"6","key":"10.1016\/j.bbacli.2014.06.003_bb0895","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1212\/WNL.0b013e3182815428","article-title":"Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma","volume":"80","author":"Krueger","year":"2013","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.bbacli.2014.06.003_bb0900","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1158\/0008-5472.CAN-09-2503","article-title":"Preclinical evaluation of radiation and perifosine in a genetically and histologically accurate model of brainstem glioma","volume":"70","author":"Becher","year":"2010","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.bbacli.2014.06.003_bb0905","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/neuonc\/noq007","article-title":"Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas","volume":"12","author":"Dougherty","year":"2010","journal-title":"Neuro Oncol."},{"issue":"4","key":"10.1016\/j.bbacli.2014.06.003_bb0910","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/pbc.22576","article-title":"Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program","volume":"55","author":"Kolb","year":"2010","journal-title":"Pediatr. Blood Cancer"},{"issue":"3","key":"10.1016\/j.bbacli.2014.06.003_bb0915","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1200\/JCO.2005.03.8638","article-title":"Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas","volume":"24","author":"Widemann","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.bbacli.2014.06.003_bb0920","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/neuonc\/noq202","article-title":"Phase II trial of tipifarnib and radiation in children with newly diagnosed diffuse intrinsic pontine gliomas","volume":"13","author":"Haas-Kogan","year":"2011","journal-title":"Neuro Oncol."},{"issue":"30","key":"10.1016\/j.bbacli.2014.06.003_bb0925","doi-asserted-by":"crossref","first-page":"5102","DOI":"10.1200\/JCO.2008.20.8975","article-title":"Phase I and pharmacokinetic study of cetuximab and irinotecan in children with refractory solid tumors: a study of the pediatric oncology experimental therapeutic investigators' consortium","volume":"27","author":"Trippett","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.bbacli.2014.06.003_bb0930","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1177\/159101991101700410","article-title":"Super-selective basilar artery infusion of bevacizumab and cetuximab for multiply recurrent pediatric ependymoma","volume":"17","author":"Rajappa","year":"2011","journal-title":"Interv. Neuroradiol."},{"issue":"2","key":"10.1016\/j.bbacli.2014.06.003_bb0935","doi-asserted-by":"crossref","first-page":"202","DOI":"10.4161\/mabs.22970","article-title":"Treatment of children with high grade glioma with nimotuzumab: a 5-y institutional experience","volume":"5","author":"Cabanas","year":"2013","journal-title":"MAbs"},{"issue":"1","key":"10.1016\/j.bbacli.2014.06.003_bb0940","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.nucmedbio.2011.07.001","article-title":"Preparation and preclinical evaluation of 177Lu-nimotuzumab targeting epidermal growth factor receptor overexpressing tumors","volume":"39","author":"Vera","year":"2012","journal-title":"Nucl. Med. Biol."},{"issue":"4","key":"10.1016\/j.bbacli.2014.06.003_bb0945","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1158\/1078-0432.CCR-06-2309","article-title":"Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma","volume":"13","author":"Vredenburgh","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.bbacli.2014.06.003_bb0950","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1093\/neuonc\/noq033","article-title":"Bevacizumab in recurrent high-grade pediatric gliomas","volume":"12","author":"Narayana","year":"2010","journal-title":"Neuro Oncol."},{"issue":"11","key":"10.1016\/j.bbacli.2014.06.003_bb0955","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1093\/neuonc\/nos213","article-title":"Lack of efficacy of bevacizumab+irinotecan in cases of pediatric recurrent ependymoma\u2014a Pediatric Brain Tumor Consortium study","volume":"14","author":"Gururangan","year":"2012","journal-title":"Neuro Oncol."},{"issue":"7","key":"10.1016\/j.bbacli.2014.06.003_bb0960","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/pbc.21935","article-title":"Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan","volume":"52","author":"Packer","year":"2009","journal-title":"Pediatr. Blood Cancer"},{"issue":"2","key":"10.1016\/j.bbacli.2014.06.003_bb0965","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1158\/1078-0432.CCR-08-1923","article-title":"Phase I and pharmacokinetic studies of erlotinib administered concurrently with radiotherapy for children, adolescents, and young adults with high-grade glioma","volume":"15","author":"Broniscer","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bbacli.2014.06.003_bb0970","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/neuonc\/noq141","article-title":"Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing\/refractory brain tumors","volume":"13","author":"Geoerger","year":"2011","journal-title":"Neuro Oncol."},{"issue":"3","key":"10.1016\/j.bbacli.2014.06.003_bb0975","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1215\/15228517-2008-095","article-title":"Antitumor effect in medulloblastoma cells by gefitinib: ectopic HER2 overexpression enhances gefitinib effects in vivo","volume":"11","author":"Meco","year":"2009","journal-title":"Neuro Oncol."},{"issue":"3","key":"10.1016\/j.bbacli.2014.06.003_bb0980","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1080\/07357900600632058","article-title":"Evaluation of gefitinib for treatment of refractory solid tumors and central nervous system malignancies in pediatric patients","volume":"24","author":"Freeman","year":"2006","journal-title":"Cancer Invest."},{"issue":"3","key":"10.1016\/j.bbacli.2014.06.003_bb0985","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1093\/neuonc\/noq199","article-title":"A phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: a report from the Pediatric Brain Tumor Consortium","volume":"13","author":"Pollack","year":"2011","journal-title":"Neuro Oncol."},{"issue":"27","key":"10.1016\/j.bbacli.2014.06.003_bb0990","doi-asserted-by":"crossref","first-page":"4221","DOI":"10.1200\/JCO.2010.28.4687","article-title":"Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study","volume":"28","author":"Fouladi","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.bbacli.2014.06.003_bb0995","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.molonc.2013.01.001","article-title":"Profiling pathway-specific novel therapeutics in preclinical assessment for central nervous system atypical teratoid rhabdoid tumors (CNS ATRT): favorable activity of targeting EGFR\u2013ErbB2 signaling with lapatinib","volume":"7","author":"Singh","year":"2013","journal-title":"Mol. Oncol."},{"issue":"5","key":"10.1016\/j.bbacli.2014.06.003_bb1000","doi-asserted-by":"crossref","first-page":"E791","DOI":"10.1002\/ijc.27377","article-title":"Effects of epidermal growth factor receptor blockade on ependymoma stem cells in vitro and in orthotopic mouse models","volume":"131","author":"Servidei","year":"2012","journal-title":"Int. J. Cancer"},{"issue":"5","key":"10.1016\/j.bbacli.2014.06.003_bb1005","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1593\/tlo.10163","article-title":"Dual inhibitor AEE788 reduces tumor growth in preclinical models of medulloblastoma","volume":"3","author":"Meco","year":"2010","journal-title":"Transl. Oncol."},{"issue":"14","key":"10.1016\/j.bbacli.2014.06.003_bb1010","doi-asserted-by":"crossref","first-page":"5987","DOI":"10.1158\/0008-5472.CAN-08-3660","article-title":"Kinome profiling in pediatric brain tumors as a new approach for target discovery","volume":"69","author":"Sikkema","year":"2009","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.bbacli.2014.06.003_bb1015","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.ejca.2005.11.023","article-title":"Mutational analysis of PDGFR-RAS\/MAPK pathway activation in childhood medulloblastoma","volume":"42","author":"Gilbertson","year":"2006","journal-title":"Eur. J. Cancer"},{"issue":"15","key":"10.1016\/j.bbacli.2014.06.003_bb1020","doi-asserted-by":"crossref","first-page":"5113","DOI":"10.1158\/1078-0432.CCR-11-0237","article-title":"Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a Children's Oncology Group study","volume":"17","author":"Dubois","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"31","key":"10.1016\/j.bbacli.2014.06.003_bb1025","doi-asserted-by":"crossref","first-page":"4762","DOI":"10.1200\/JCO.2010.30.3545","article-title":"Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma","volume":"28","author":"Broniscer","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.bbacli.2014.06.003_bb1030","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1158\/1078-0432.CCR-13-0306","article-title":"Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma","volume":"19","author":"Broniscer","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"8 Suppl. 847","key":"10.1016\/j.bbacli.2014.06.003_bb1035","article-title":"AACR 103rd Annual Meeting, Abstract 847: Foretinib, a multi-kinase inhibitor of cMET and PDGFR\u03b1, in the treatment of disseminated medulloblastoma","volume":"72","author":"Faria","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbacli.2014.06.003_bb1040","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/1471-2407-12-80","article-title":"Polo-like kinase 1 (PLK1) inhibition suppresses cell growth and enhances radiation sensitivity in medulloblastoma cells","volume":"12","author":"Harris","year":"2012","journal-title":"BMC Cancer"},{"issue":"16","key":"10.1016\/j.bbacli.2014.06.003_bb1045","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1200\/JCO.2004.10.103","article-title":"Results of a phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumor","volume":"22","author":"Stewart","year":"2004","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.bbacli.2014.06.003_bb1050","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/pbc.22347","article-title":"Thiotepa\/topotecan\/carboplatin with autologous stem cell rescue in recurrent\/refractory\/poor prognosis pediatric malignancies of the central nervous system","volume":"54","author":"Gilheeney","year":"2010","journal-title":"Pediatr. Blood Cancer"},{"issue":"2","key":"10.1016\/j.bbacli.2014.06.003_bb1055","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1093\/neuonc\/4.2.102","article-title":"Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience","volume":"4","author":"Turner","year":"2002","journal-title":"Neuro Oncol."},{"issue":"29","key":"10.1016\/j.bbacli.2014.06.003_bb1060","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1200\/JCO.2007.11.6103","article-title":"Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group study","volume":"25","author":"Bomgaars","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.bbacli.2014.06.003_bb1065","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00381-012-2013-4","article-title":"Response to bevacizumab, irinotecan, and temozolomide in children with relapsed medulloblastoma: a multi-institutional experience","volume":"29","author":"Aguilera","year":"2013","journal-title":"Childs Nerv. Syst."},{"issue":"16","key":"10.1016\/j.bbacli.2014.06.003_bb1070","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1016\/j.ejca.2010.05.016","article-title":"Phase I study of temozolomide combined with oral etoposide in children with recurrent or progressive medulloblastoma","volume":"46","author":"Ruggiero","year":"2010","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"10.1016\/j.bbacli.2014.06.003_bb1075","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/mpo.10137","article-title":"Activity of postoperative carboplatin, etoposide, and high-dose methotrexate in pediatric CNS embryonal tumors: results of a phase II study in newly diagnosed children","volume":"39","author":"Kellie","year":"2002","journal-title":"Med. Pediatr. Oncol."},{"issue":"2","key":"10.1016\/j.bbacli.2014.06.003_bb1080","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/pbc.23016","article-title":"Testing of the topoisomerase 1 inhibitor Genz-644282 by the pediatric preclinical testing program","volume":"58","author":"Houghton","year":"2012","journal-title":"Pediatr. Blood Cancer"},{"issue":"3","key":"10.1016\/j.bbacli.2014.06.003_bb1085","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1158\/1078-0432.CCR-10-0738","article-title":"Phase 1 study of valproic acid in pediatric patients with refractory solid or CNS tumors: a children's oncology group report","volume":"17","author":"Su","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.bbacli.2014.06.003_bb1090","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/neuonc\/nor208","article-title":"Histone deacetylase inhibition decreases proliferation and potentiates the effect of ionizing radiation in atypical teratoid\/rhabdoid tumor cells","volume":"14","author":"Knipstein","year":"2012","journal-title":"Neuro Oncol."},{"issue":"3","key":"10.1016\/j.bbacli.2014.06.003_bb1095","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s11060-012-0978-1","article-title":"HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment","volume":"110","author":"Milde","year":"2012","journal-title":"J. Neurooncol"},{"issue":"9","key":"10.1016\/j.bbacli.2014.06.003_bb1100","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1002\/pbc.24541","article-title":"A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study","volume":"60","author":"Hummel","year":"2013","journal-title":"Pediatr. Blood Cancer"},{"issue":"3","key":"10.1016\/j.bbacli.2014.06.003_bb1105","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1750-3639.2012.00633.x","article-title":"Aurora kinase B is a potential therapeutic target in pediatric diffuse intrinsic pontine glioma","volume":"23","author":"Buczkowicz","year":"2013","journal-title":"Brain Pathol."},{"issue":"5","key":"10.1016\/j.bbacli.2014.06.003_bb1110","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.3892\/or.2012.1996","article-title":"17AEP-GA, an HSP90 antagonist, is a potent inhibitor of glioblastoma cell proliferation, survival, migration and invasion","volume":"28","author":"Miekus","year":"2012","journal-title":"Oncol. Rep."},{"issue":"5","key":"10.1016\/j.bbacli.2014.06.003_bb1115","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1158\/1535-7163.MCT-09-0683","article-title":"Mechanistic evaluation of the novel HSP90 inhibitor NVP-AUY922 in adult and pediatric glioblastoma","volume":"9","author":"Gaspar","year":"2010","journal-title":"Mol. Cancer Ther."},{"issue":"6","key":"10.1016\/j.bbacli.2014.06.003_bb1120","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1158\/1078-0432.CCR-06-2270","article-title":"A phase I study of 17-allylaminogeldanamycin in relapsed\/refractory pediatric patients with solid tumors: a Children's Oncology Group study","volume":"13","author":"Weigel","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.bbacli.2014.06.003_bb1125","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.pediatrneurol.2012.02.005","article-title":"Biologically targeted therapeutics in pediatric brain tumors","volume":"46","author":"Nageswara Rao","year":"2012","journal-title":"Pediatr. Neurol."},{"issue":"2","key":"10.1016\/j.bbacli.2014.06.003_bb1130","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/pr.2012.54","article-title":"Pediatric sarcomas: translating molecular pathogenesis of disease to novel therapeutic possibilities","volume":"72","author":"Anderson","year":"2012","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.bbacli.2014.06.003_bb1135","doi-asserted-by":"crossref","first-page":"627254","DOI":"10.1155\/2012\/627254","article-title":"The genetics of osteosarcoma","volume":"2012","author":"Martin","year":"2012","journal-title":"Sarcoma"},{"issue":"4","key":"10.1016\/j.bbacli.2014.06.003_bb1140","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1177\/0022034511421490","article-title":"Childhood rhabdomyosarcoma: recent advances and prospective views","volume":"91","author":"Wang","year":"2012","journal-title":"J. Dent. Res."},{"issue":"4","key":"10.1016\/j.bbacli.2014.06.003_bb1145","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/CCO.0b013e328303ba1d","article-title":"Ewing sarcoma: historical perspectives, current state-of-the-art, and opportunities for targeted therapy in the future","volume":"20","author":"Ludwig","year":"2008","journal-title":"Curr. Opin. Oncol."},{"issue":"16","key":"10.1016\/j.bbacli.2014.06.003_bb1150","doi-asserted-by":"crossref","first-page":"7275","DOI":"10.1128\/MCB.24.16.7275-7283.2004","article-title":"EWS\/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3","volume":"24","author":"Prieur","year":"2004","journal-title":"Mol. Cell. Biol."},{"issue":"12","key":"10.1016\/j.bbacli.2014.06.003_bb1155","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1158\/1541-7786.MCR-08-0054","article-title":"EWS-Fli1 up-regulates expression of the Aurora A and Aurora B kinases","volume":"6","author":"Wakahara","year":"2008","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.bbacli.2014.06.003_bb1160","first-page":"9","article-title":"Type 1 insulin growth factor receptor targeted therapies in pediatric cancer","volume":"3","author":"Wager","year":"2013","journal-title":"Front. Oncol."},{"issue":"12","key":"10.1016\/j.bbacli.2014.06.003_bb1165","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1158\/1535-7163.MCT-09-0499","article-title":"BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R\/IR","volume":"8","author":"Carboni","year":"2009","journal-title":"Mol. Cancer Ther."},{"issue":"9","key":"10.1016\/j.bbacli.2014.06.003_bb1170","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.1158\/0008-5472.CAN-04-3192","article-title":"Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors","volume":"65","author":"Scotlandi","year":"2005","journal-title":"Cancer Res."},{"issue":"34","key":"10.1016\/j.bbacli.2014.06.003_bb1175","doi-asserted-by":"crossref","first-page":"5800","DOI":"10.1200\/JCO.2009.23.6745","article-title":"Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1","volume":"27","author":"Tolcher","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"34","key":"10.1016\/j.bbacli.2014.06.003_bb1180","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2010.34.0000","article-title":"R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study","volume":"29","author":"Pappo","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"34","key":"10.1016\/j.bbacli.2014.06.003_bb1185","doi-asserted-by":"crossref","first-page":"4534","DOI":"10.1200\/JCO.2010.33.0670","article-title":"Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma","volume":"29","author":"Juergens","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.bbacli.2014.06.003_bb1190","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1200\/JCO.2011.37.4355","article-title":"Phase I\/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group","volume":"30","author":"Malempati","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.bbacli.2014.06.003_bb1195","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1158\/1535-7163.MCT-11-0100","article-title":"An integrated chemical biology approach identifies specific vulnerability of Ewing's sarcoma to combined inhibition of Aurora kinases A and B","volume":"10","author":"Winter","year":"2011","journal-title":"Mol. Cancer Ther."},{"issue":"22","key":"10.1016\/j.bbacli.2014.06.003_bb1200","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1093\/jnci\/94.22.1673","article-title":"Potential use of imatinib in Ewing's Sarcoma: evidence for in vitro and in vivo activity","volume":"94","author":"Merchant","year":"2002","journal-title":"J. Natl. Cancer Inst."},{"issue":"2","key":"10.1016\/j.bbacli.2014.06.003_bb1205","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/pbc.21132","article-title":"A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study","volume":"50","author":"Bond","year":"2008","journal-title":"Pediatr. Blood Cancer"},{"issue":"2","key":"10.1016\/j.bbacli.2014.06.003_bb1210","first-page":"547","article-title":"Phase II clinical trial of imatinib mesylate in therapy of KIT and\/or PDGFRalpha-expressing Ewing sarcoma family of tumors and desmoplastic small round cell tumors","volume":"30","author":"Chao","year":"2010","journal-title":"Anticancer Res."},{"issue":"3","key":"10.1016\/j.bbacli.2014.06.003_bb1215","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/pbc.24016","article-title":"Initial testing of the multitargeted kinase inhibitor pazopanib by the Pediatric Preclinical Testing Program","volume":"59","author":"Keir","year":"2012","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.bbacli.2014.06.003_bb1220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1475-2867-8-1","article-title":"Proliferation of Ewing sarcoma cell lines is suppressed by the receptor tyrosine kinase inhibitors gefitinib and vandetanib","volume":"8","author":"Andersson","year":"2008","journal-title":"Cancer Cell Int."},{"issue":"2","key":"10.1016\/j.bbacli.2014.06.003_bb1225","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/ijc.28047","article-title":"Expression and clinical relevance of MET and ALK in Ewing sarcomas","volume":"133","author":"Fleuren","year":"2013","journal-title":"Int. J. Cancer"},{"issue":"3","key":"10.1016\/j.bbacli.2014.06.003_bb1230","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/pbc.21988","article-title":"Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program","volume":"53","author":"Keshelava","year":"2009","journal-title":"Pediatr. Blood Cancer"},{"issue":"1","key":"10.1016\/j.bbacli.2014.06.003_bb1235","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/pbc.23154","article-title":"Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program","volume":"59","author":"Kang","year":"2012","journal-title":"Pediatr. Blood Cancer"},{"issue":"8","key":"10.1016\/j.bbacli.2014.06.003_bb1240","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/cncr.21780","volume":"106","author":"Milano","year":"2006","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.bbacli.2014.06.003_bb1245","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1002\/pbc.22206","article-title":"Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan\u2013Kettering experience","volume":"53","author":"Casey","year":"2009","journal-title":"Pediatr. Blood Cancer"},{"issue":"5","key":"10.1016\/j.bbacli.2014.06.003_bb1250","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1097\/MPH.0b013e318270a343","article-title":"Cyclophosphamide and topotecan as first-line salvage therapy in patients with relapsed Ewing sarcoma at a single institution","volume":"35","author":"Farhat","year":"2012","journal-title":"J. Pediatr. Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.bbacli.2014.06.003_bb1255","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3109\/08880018.2013.767868","article-title":"A modified protocol with vincristine, topotecan, and cyclophosphamide for recurrent\/progressive Ewing sarcoma family tumors","volume":"30","author":"Kebudi","year":"2013","journal-title":"Pediatr. Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.bbacli.2014.06.003_bb1260","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.bcp.2012.04.005","article-title":"The curative efficacy of namitecan (ST1968) in preclinical models of pediatric sarcoma is associated with antiangiogenic effects","volume":"84","author":"Cassinelli","year":"2012","journal-title":"Biochem. Pharmacol."},{"issue":"2","key":"10.1016\/j.bbacli.2014.06.003_bb1265","first-page":"266","article-title":"Targeting receptor tyrosine kinases in osteosarcoma and Ewing sarcoma: current hurdles and future perspectives","volume":"1845","author":"Fleuren","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"issue":"7","key":"10.1016\/j.bbacli.2014.06.003_bb1270","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s12094-007-0079-3","article-title":"Molecular biology of rhabdomyosarcoma","volume":"9","author":"Gallego Melcon","year":"2007","journal-title":"Clin. Transl. Oncol."},{"issue":"23","key":"10.1016\/j.bbacli.2014.06.003_bb1275","doi-asserted-by":"crossref","first-page":"13164","DOI":"10.1073\/pnas.93.23.13164","article-title":"Induction of apoptosis in rhabdomyosarcoma cells through down-regulation of PAX proteins","volume":"93","author":"Bernasconi","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"Suppl.","key":"10.1016\/j.bbacli.2014.06.003_bb1280","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/S0304-3835(00)00649-2","article-title":"Regulating the neoplastic phenotype using engineered transcriptional repressors","volume":"162","author":"Fredericks","year":"2001","journal-title":"Cancer Lett."},{"issue":"6","key":"10.1016\/j.bbacli.2014.06.003_bb1285","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1007\/s00262-004-0625-6","article-title":"Lack of effective T-lymphocyte response to the PAX3\/FKHR translocation area in alveolar rhabdomyosarcoma","volume":"54","author":"Rodeberg","year":"2005","journal-title":"Cancer Immunol. Immunother."},{"issue":"18","key":"10.1016\/j.bbacli.2014.06.003_bb1290","first-page":"4882","article-title":"All-trans-retinoic acid inhibits the growth of human rhabdomyosarcoma cell lines","volume":"51","author":"Crouch","year":"1991","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.bbacli.2014.06.003_bb1295","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1006\/excr.1993.1239","article-title":"TPA-induced differentiation of human rhabdomyosarcoma cells: expression of the myogenic regulatory factors","volume":"208","author":"Bouche","year":"1993","journal-title":"Exp. Cell Res."},{"issue":"1","key":"10.1016\/j.bbacli.2014.06.003_bb1300","doi-asserted-by":"crossref","first-page":"e55072","DOI":"10.1371\/journal.pone.0055072","article-title":"A. Boro, and B.W. Schafer, Cell-based small-molecule compound screen identifies fenretinide as potential therapeutic for translocation-positive rhabdomyosarcoma","volume":"8","author":"Herrero Martin","year":"2013","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.bbacli.2014.06.003_bb1305","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1038\/nm787","article-title":"Synergism between INK4a\/ARF inactivation and aberrant HGF\/SF signaling in rhabdomyosarcomagenesis","volume":"8","author":"Sharp","year":"2002","journal-title":"Nat. Med."},{"issue":"9","key":"10.1016\/j.bbacli.2014.06.003_bb1310","doi-asserted-by":"crossref","first-page":"4742","DOI":"10.1158\/0008-5472.CAN-05-4292","article-title":"Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma","volume":"66","author":"Taulli","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbacli.2014.06.003_bb1315","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/1479-5876-9-64","article-title":"Inhibition of phosphorylated c-Met in rhabdomyosarcoma cell lines by a small molecule inhibitor SU11274","volume":"9","author":"Hou","year":"2011","journal-title":"J. Transl. Med."},{"issue":"7","key":"10.1016\/j.bbacli.2014.06.003_bb1320","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1128\/MCB.18.7.4118","article-title":"Tumor-specific PAX3-FKHR transcription factor, but not PAX3, activates the platelet-derived growth factor alpha receptor","volume":"18","author":"Epstein","year":"1998","journal-title":"Mol. Cell. Biol."},{"issue":"51","key":"10.1016\/j.bbacli.2014.06.003_bb1325","doi-asserted-by":"crossref","first-page":"6550","DOI":"10.1038\/onc.2008.255","article-title":"PDGFR-A is a therapeutic target in alveolar rhabdomyosarcoma","volume":"27","author":"Taniguchi","year":"2008","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.bbacli.2014.06.003_bb1330","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1158\/0008-5472.CAN-12-1646","article-title":"Distinct effects of ligand-induced PDGFRalpha and PDGFRbeta signaling in the human rhabdomyosarcoma tumor cell and stroma cell compartments","volume":"73","author":"Ehnman","year":"2013","journal-title":"Cancer Res."},{"issue":"21","key":"10.1016\/j.bbacli.2014.06.003_bb1335","first-page":"5531","article-title":"In vivo treatment with antibody against IGF-1 receptor suppresses growth of human rhabdomyosarcoma and down-regulates p34cdc2","volume":"54","author":"Kalebic","year":"1994","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.bbacli.2014.06.003_bb1340","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/pbc.22367","article-title":"Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program","volume":"54","author":"Houghton","year":"2010","journal-title":"Pediatr. Blood Cancer"},{"issue":"48","key":"10.1016\/j.bbacli.2014.06.003_bb1345","doi-asserted-by":"crossref","first-page":"6367","DOI":"10.1038\/onc.2010.364","article-title":"Insulin-like growth factor 1 receptor antibody induces rhabdomyosarcoma cell death via a process involving AKT and Bcl-x(L)","volume":"29","author":"Mayeenuddin","year":"2010","journal-title":"Oncogene"},{"issue":"13","key":"10.1016\/j.bbacli.2014.06.003_bb1350","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1038\/sj.onc.1209990","article-title":"Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism","volume":"26","author":"Wan","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.bbacli.2014.06.003_bb1355","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1476-4598-5-31","article-title":"Down-regulation of c-Myc following MEK\/ERK inhibition halts the expression of malignant phenotype in rhabdomyosarcoma and in non muscle-derived human tumors","volume":"5","author":"Marampon","year":"2006","journal-title":"Mol. Cancer"},{"issue":"3","key":"10.1016\/j.bbacli.2014.06.003_bb1360","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1158\/1535-7163.MCT-08-0570","article-title":"MEK\/ERK inhibitor U0126 affects in vitro and in vivo growth of embryonal rhabdomyosarcoma","volume":"8","author":"Marampon","year":"2009","journal-title":"Mol. Cancer Ther."},{"issue":"3","key":"10.1016\/j.bbacli.2014.06.003_bb1365","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1200\/JCO.2011.37.8588","article-title":"Anaplastic lymphoma kinase aberrations in rhabdomyosarcoma: clinical and prognostic implications","volume":"30","author":"van Gaal","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"16","key":"10.1016\/j.bbacli.2014.06.003_bb1370","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1016\/j.ejca.2013.06.022","article-title":"Simultaneous targeting of insulin-like growth factor-1 receptor and anaplastic lymphoma kinase in embryonal and alveolar rhabdomyosarcoma: a rational choice","volume":"49","author":"van Gaal","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bbacli.2014.06.003_bb1375","doi-asserted-by":"crossref","first-page":"130484","DOI":"10.1155\/2011\/130484","article-title":"Preclinical testing of erlotinib in a transgenic alveolar rhabdomyosarcoma mouse model","volume":"2011","author":"Abraham","year":"2011","journal-title":"Sarcoma"},{"issue":"1","key":"10.1016\/j.bbacli.2014.06.003_bb1380","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/pbc.21508","article-title":"Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program","volume":"51","author":"Smith","year":"2008","journal-title":"Pediatr. Blood Cancer"},{"issue":"3","key":"10.1016\/j.bbacli.2014.06.003_bb1385","first-page":"161","article-title":"High anti tumor activity against rhabdomyosarcoma cells and low normal cells cytotoxicity of heat shock protein 90 inhibitors, with special emphasis on 17-[2-(pyrrolidin-1-yl)ethyl]-aminno-17-demethoxygeldanamycin","volume":"60","author":"Lukasiewicz","year":"2009","journal-title":"J. Physiol. Pharmacol."},{"issue":"4","key":"10.1016\/j.bbacli.2014.06.003_bb1390","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/pbc.20227","article-title":"Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent\/refractory sarcoma: the Children's Cancer Group (CCG) experience","volume":"44","author":"Van Winkle","year":"2005","journal-title":"Pediatr. Blood Cancer"},{"issue":"4","key":"10.1016\/j.bbacli.2014.06.003_bb1395","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/pbc.21494","article-title":"Treatment of children with metastatic soft tissue sarcoma with oral maintenance compared to high dose chemotherapy: report of the HD CWS-96 trial","volume":"50","author":"Klingebiel","year":"2008","journal-title":"Pediatr. Blood Cancer"},{"issue":"4","key":"10.1016\/j.bbacli.2014.06.003_bb1400","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1200\/JCO.2006.06.1960","article-title":"Phase II trial of irinotecan in children with relapsed or refractory rhabdomyosarcoma: a joint study of the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group","volume":"25","author":"Vassal","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.bbacli.2014.06.003_bb1405","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1200\/JCO.2006.07.1720","article-title":"Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group","volume":"25","author":"Pappo","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bbacli.2014.06.003_bb1410","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s12032-008-9085-8","article-title":"Efficacy of topotecan plus vincristine and doxorubicin in children with recurrent\/refractory rhabdomyosarcoma","volume":"26","author":"Meazza","year":"2009","journal-title":"Med. Oncol."},{"issue":"6","key":"10.1016\/j.bbacli.2014.06.003_bb1415","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/pbc.24435","article-title":"Children's Oncology Group's 2013 blueprint for research: soft tissue sarcomas","volume":"60","author":"Hawkins","year":"2013","journal-title":"Pediatr. Blood Cancer"},{"issue":"4","key":"10.1016\/j.bbacli.2014.06.003_bb1420","first-page":"823","article-title":"Downregulation of SS18\u2013SSX1 expression in synovial sarcoma by small interfering RNA enhances the focal adhesion pathway and inhibits anchorage-independent growth in vitro and tumor growth in vivo","volume":"36","author":"Takenaka","year":"2010","journal-title":"Int. J. Oncol."},{"issue":"5","key":"10.1016\/j.bbacli.2014.06.003_bb1425","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/S0002-9440(10)64437-9","article-title":"Expression profiling of synovial sarcoma by cDNA microarrays: association of ERBB2, IGFBP2, and ELF3 with epithelial differentiation","volume":"161","author":"Allander","year":"2002","journal-title":"Am. J. Pathol."},{"issue":"4","key":"10.1016\/j.bbacli.2014.06.003_bb1430","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S0002-9440(10)63502-X","article-title":"Tissue microarray validation of epidermal growth factor receptor and SALL2 in synovial sarcoma with comparison to tumors of similar histology","volume":"163","author":"Nielsen","year":"2003","journal-title":"Am. J. Pathol."},{"issue":"1","key":"10.1016\/j.bbacli.2014.06.003_bb1435","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cancergencyto.2009.03.008","article-title":"Molecular and immunohistochemical analyses of BCL2, KI-67, and cyclin D1 expression in synovial sarcoma","volume":"193","author":"Krskova","year":"2009","journal-title":"Cancer Genet. Cytogenet."},{"issue":"4","key":"10.1016\/j.bbacli.2014.06.003_bb1440","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/path.2438","article-title":"Insulin-like growth factor-1 receptor acts as a growth regulator in synovial sarcoma","volume":"216","author":"Friedrichs","year":"2008","journal-title":"J. Pathol."},{"issue":"4","key":"10.1016\/j.bbacli.2014.06.003_bb1445","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1634\/theoncologist.2008-0065","article-title":"A phase II study of gefitinib for patients with advanced HER-1 expressing synovial sarcoma refractory to doxorubicin-containing regimens","volume":"13","author":"Ray-Coquard","year":"2008","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.bbacli.2014.06.003_bb1450","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1002\/jor.20087","article-title":"G3139 antisense oligonucleotide directed against antiapoptotic Bcl-2 enhances doxorubicin cytotoxicity in the FU-SY-1 synovial sarcoma cell line","volume":"24","author":"Joyner","year":"2006","journal-title":"J. Orthop. Res."},{"issue":"12","key":"10.1016\/j.bbacli.2014.06.003_bb1455","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1200\/JCO.2006.09.5125","article-title":"Phase I trial of G3139, a bcl-2 antisense oligonucleotide, combined with doxorubicin and cyclophosphamide in children with relapsed solid tumors: a Children's Oncology Group Study","volume":"25","author":"Rheingold","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.bbacli.2014.06.003_bb1460","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/s11912-009-0061-z","article-title":"Critical signaling pathways in bone sarcoma: candidates for therapeutic interventions","volume":"11","author":"Geryk-Hall","year":"2009","journal-title":"Curr. Oncol. Rep."},{"issue":"9","key":"10.1016\/j.bbacli.2014.06.003_bb1465","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1007\/s11999-008-0338-9","article-title":"Specific tyrosine kinase inhibitors regulate human osteosarcoma cells in vitro","volume":"466","author":"Messerschmitt","year":"2008","journal-title":"Clin. Orthop. Relat. Res."},{"issue":"6","key":"10.1016\/j.bbacli.2014.06.003_bb1470","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/pbc.21450","article-title":"Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program","volume":"50","author":"Kolb","year":"2008","journal-title":"Pediatr. Blood Cancer"},{"issue":"2","key":"10.1016\/j.bbacli.2014.06.003_bb1475","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1158\/1535-7163.MCT-09-0555","article-title":"A fully human insulin-like growth factor-I receptor antibody SCH 717454 (robatumumab) has antitumor activity as a single agent and in combination with cytotoxics in pediatric tumor xenografts","volume":"9","author":"Wang","year":"2010","journal-title":"Mol. Cancer Ther."},{"issue":"3","key":"10.1016\/j.bbacli.2014.06.003_bb1480","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1158\/1078-0432.CCR-10-1731","article-title":"Pharmacokinetically guided phase 1 trial of the IGF-1 receptor antagonist RG1507 in children with recurrent or refractory solid tumors","volume":"17","author":"Bagatell","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.bbacli.2014.06.003_bb1485","doi-asserted-by":"crossref","first-page":"202","DOI":"10.4143\/crt.2012.44.3.202","article-title":"Epidermal growth factor receptor: is it a feasible target for the treatment of osteosarcoma?","volume":"44","author":"Lee","year":"2012","journal-title":"Cancer Res. Treat."},{"issue":"5","key":"10.1016\/j.bbacli.2014.06.003_bb1490","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s10024-005-0044-5","article-title":"HER2 amplification and overexpression is not present in pediatric osteosarcoma: a tissue microarray study","volume":"8","author":"Somers","year":"2005","journal-title":"Pediatr. Dev. Pathol."},{"issue":"2","key":"10.1016\/j.bbacli.2014.06.003_bb1495","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/pbc.21576","article-title":"C-erbB-2 expression and prognostic significance in osteosarcoma","volume":"51","author":"Yal\u00e7in","year":"2008","journal-title":"Pediatr. Blood Cancer"},{"issue":"20","key":"10.1016\/j.bbacli.2014.06.003_bb1500","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1200\/JCO.2011.37.4546","article-title":"Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the Children's Oncology Group","volume":"30","author":"Ebb","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.bbacli.2014.06.003_bb1505","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1002\/cncr.23437","article-title":"Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma","volume":"112","author":"Kubo","year":"2008","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.bbacli.2014.06.003_bb1510","first-page":"3584","article-title":"Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571","volume":"8","author":"McGary","year":"2002","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.bbacli.2014.06.003_bb1515","doi-asserted-by":"crossref","first-page":"4750","DOI":"10.1158\/0008-5472.CAN-05-4422","article-title":"MET overexpression turns human primary osteoblasts into osteosarcomas","volume":"66","author":"Patane","year":"2006","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.bbacli.2014.06.003_bb1520","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1096\/fj.02-0576fje","article-title":"Role of the MET\/HGF receptor in proliferation and invasive behavior of osteosarcoma","volume":"17","author":"Coltella","year":"2003","journal-title":"FASEB J."},{"issue":"12","key":"10.1016\/j.bbacli.2014.06.003_bb1525","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1111\/j.1349-7006.2009.01310.x","article-title":"Functional genome screen for therapeutic targets of osteosarcoma","volume":"100","author":"Yamaguchi","year":"2009","journal-title":"Cancer Sci."},{"issue":"8","key":"10.1016\/j.bbacli.2014.06.003_bb1530","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1093\/hmg\/ddp057","article-title":"Notch signalling contributes to the pathogenesis of human osteosarcomas","volume":"18","author":"Engin","year":"2009","journal-title":"Hum. Mol. Genet."},{"issue":"5","key":"10.1016\/j.bbacli.2014.06.003_bb1535","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1002\/pbc.23290","article-title":"Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a gamma-secretase inhibitor targeting notch signaling","volume":"58","author":"Kolb","year":"2012","journal-title":"Pediatr. Blood Cancer"},{"issue":"8","key":"10.1016\/j.bbacli.2014.06.003_bb1540","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/pbc.25026","article-title":"Initial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program","volume":"61","author":"Carol","year":"2014","journal-title":"Pediatr. Blood Cancer"},{"issue":"4","key":"10.1016\/j.bbacli.2014.06.003_bb1545","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/jcb.24708","article-title":"Wnt pathway in osteosarcoma, from oncogenic to therapeutic","volume":"115","author":"Cai","year":"2014","journal-title":"J. Cell. Biochem."},{"issue":"3","key":"10.1016\/j.bbacli.2014.06.003_bb1550","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/pbc.21595","article-title":"Wnt10b induces chemotaxis of osteosarcoma and correlates with reduced survival","volume":"51","author":"Chen","year":"2008","journal-title":"Pediatr. Blood Cancer"},{"issue":"2","key":"10.1016\/j.bbacli.2014.06.003_bb1555","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.bbrc.2012.12.118","article-title":"Inhibition of the Wnt-beta-catenin and Notch signaling pathways sensitizes osteosarcoma cells to chemotherapy","volume":"431","author":"Ma","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"7","key":"10.1016\/j.bbacli.2014.06.003_bb1560","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1002\/pbc.22710","article-title":"Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program","volume":"55","author":"Carol","year":"2010","journal-title":"Pediatr. Blood Cancer"},{"issue":"3","key":"10.1016\/j.bbacli.2014.06.003_bb1565","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/pbc.23412","article-title":"Testing of the Akt\/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing Program","volume":"59","author":"Gorlick","year":"2012","journal-title":"Pediatr. Blood Cancer"},{"issue":"4","key":"10.1016\/j.bbacli.2014.06.003_bb1570","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1002\/pbc.21296","article-title":"Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program","volume":"50","author":"Houghton","year":"2008","journal-title":"Pediatr. Blood Cancer"},{"issue":"8","key":"10.1016\/j.bbacli.2014.06.003_bb1575","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1158\/1078-0432.CCR-12-2293","article-title":"The combination of sorafenib and everolimus abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models","volume":"19","author":"Pignochino","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"58","key":"10.1016\/j.bbacli.2014.06.003_bb1580","doi-asserted-by":"crossref","first-page":"9231","DOI":"10.1038\/sj.onc.1207184","article-title":"FR901228 induces tumor regression associated with induction of Fas ligand and activation of Fas signaling in human osteosarcoma cells","volume":"22","author":"Imai","year":"2003","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.bbacli.2014.06.003_bb1585","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1023\/B:APPT.0000038037.68908.6e","article-title":"Mechanism of histone deacetylase inhibitor Trichostatin A induced apoptosis in human osteosarcoma cells","volume":"9","author":"Roh","year":"2004","journal-title":"Apoptosis"},{"issue":"4","key":"10.1016\/j.bbacli.2014.06.003_bb1590","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2174\/1568009611313040005","article-title":"The histone deacetylase inhibitor, MS-275 (entinostat), downregulates c-FLIP, sensitizes osteosarcoma cells to FasL, and induces the regression of osteosarcoma lung metastases","volume":"13","author":"Rao-Bindal","year":"2013","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.bbacli.2014.06.003_bb1595","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.coph.2014.02.002","article-title":"Recent advances in osteosarcoma","volume":"16","author":"Botter","year":"2014","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.bbacli.2014.06.003_bb1600","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-13-2574","article-title":"Towards a drug development path that targets metastatic progression in osteosarcoma","author":"Khanna","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"33","key":"10.1016\/j.bbacli.2014.06.003_bb1605","doi-asserted-by":"crossref","first-page":"4877","DOI":"10.1200\/JCO.2009.26.5983","article-title":"Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers","volume":"28","author":"Von Hoff","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bbacli.2014.06.003_bb1610","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1158\/2159-8274.CD-10-0010","article-title":"The BATTLE trial: personalizing therapy for lung cancer","volume":"1","author":"Kim","year":"2011","journal-title":"Cancer Discov."},{"issue":"5","key":"10.1016\/j.bbacli.2014.06.003_bb1615","first-page":"1079","article-title":"There are no bad anticancer agents, only bad clinical trial designs\u2014twenty-first Richard and Hinda Rosenthal Foundation Award Lecture","volume":"4","author":"Von Hoff","year":"1998","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.bbacli.2014.06.003_bb1620","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrclinonc.2009.38","article-title":"Next generation oncology drug development: opportunities and challenges","volume":"6","author":"Gutierrez","year":"2009","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.bbacli.2014.06.003_bb1625","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1200\/JCO.2005.01.112","article-title":"Clinical trial designs for predictive marker validation in cancer treatment trials","volume":"23","author":"Sargent","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.bbacli.2014.06.003_bb1630","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1002\/humu.21078","article-title":"Genetic variations as cancer prognostic markers: review and update","volume":"30","author":"Savas","year":"2009","journal-title":"Hum. Mutat."},{"issue":"Suppl. 1","key":"10.1016\/j.bbacli.2014.06.003_bb1635","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1517\/14728222.2011.637921","article-title":"The paradigm of personalized therapy in oncology","volume":"16","author":"Gasparini","year":"2012","journal-title":"Expert Opin. Ther. Targets"},{"issue":"7","key":"10.1016\/j.bbacli.2014.06.003_bb1640","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/nbt.2284","article-title":"Combinatorial drug therapy for cancer in the post-genomic era","volume":"30","author":"Al-Lazikani","year":"2012","journal-title":"Nat. Biotechnol."},{"issue":"6127","key":"10.1016\/j.bbacli.2014.06.003_bb1645","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1126\/science.1235122","article-title":"Cancer genome landscapes","volume":"339","author":"Vogelstein","year":"2013","journal-title":"Science"}],"container-title":["BBA Clinical"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214647414000105?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214647414000105?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T16:24:35Z","timestamp":1778862275000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214647414000105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":329,"alternative-id":["S2214647414000105"],"URL":"https:\/\/doi.org\/10.1016\/j.bbacli.2014.06.003","relation":{},"ISSN":["2214-6474"],"issn-type":[{"value":"2214-6474","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular profiling of childhood cancer: Biomarkers and novel therapies","name":"articletitle","label":"Article Title"},{"value":"BBA Clinical","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbacli.2014.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}